Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

437 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation.
Slattery JT, Clift RA, Buckner CD, Radich J, Storer B, Bensinger WI, Soll E, Anasetti C, Bowden R, Bryant E, Chauncey T, Deeg HJ, Doney KC, Flowers M, Gooley T, Hansen JA, Martin PJ, McDonald GB, Nash R, Petersdorf EW, Sanders JE, Schoch G, Stewart P, Storb R, Sullivan KM, Thomas ED, Witherspoon RP, Appelbaum FR. Slattery JT, et al. Among authors: anasetti c. Blood. 1997 Apr 15;89(8):3055-60. Blood. 1997. PMID: 9108427 Free article.
A humanized non-FcR-binding anti-CD3 antibody, visilizumab, for treatment of steroid-refractory acute graft-versus-host disease.
Carpenter PA, Appelbaum FR, Corey L, Deeg HJ, Doney K, Gooley T, Krueger J, Martin P, Pavlovic S, Sanders J, Slattery J, Levitt D, Storb R, Woolfrey A, Anasetti C. Carpenter PA, et al. Among authors: anasetti c. Blood. 2002 Apr 15;99(8):2712-9. doi: 10.1182/blood.v99.8.2712. Blood. 2002. PMID: 11929757 Free article. Clinical Trial.
Hematopoietic stem cell transplantation for advanced myelodysplastic syndrome after conditioning with busulfan and fractionated total body irradiation is associated with low relapse rate but considerable nonrelapse mortality.
Jurado M, Deeg HJ, Storer B, Anasetti C, Anderson JE, Bryant E, Chauncey T, Doney K, Flowers ME, Hansen J, Martin PJ, Nash RA, Petersdorf E, Radich J, Sale G, Sandmaier BM, Storb R, Wade J, Witherspoon R, Appelbaum FR. Jurado M, et al. Among authors: anasetti c. Biol Blood Marrow Transplant. 2002;8(3):161-9. doi: 10.1053/bbmt.2002.v8.pm11939606. Biol Blood Marrow Transplant. 2002. PMID: 11939606 Free article. Clinical Trial.
Psoralen and ultraviolet A irradiation (PUVA) as therapy for steroid-resistant cutaneous acute graft-versus-host disease.
Furlong T, Leisenring W, Storb R, Anasetti C, Appelbaum FR, Carpenter PA, Deeg HJ, Doney K, Kiem HP, Nash RA, Sanders JE, Witherspoon R, Thompson D, Martin PJ. Furlong T, et al. Among authors: anasetti c. Biol Blood Marrow Transplant. 2002;8(4):206-12. doi: 10.1053/bbmt.2002.v8.pm12014809. Biol Blood Marrow Transplant. 2002. PMID: 12014809 Free article.
Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome.
Deeg HJ, Storer B, Slattery JT, Anasetti C, Doney KC, Hansen JA, Kiem HP, Martin PJ, Petersdorf E, Radich JP, Sanders JE, Shulman HM, Warren EH, Witherspoon RP, Bryant EM, Chauncey TR, Getzendaner L, Storb R, Appelbaum FR. Deeg HJ, et al. Among authors: anasetti c. Blood. 2002 Aug 15;100(4):1201-7. doi: 10.1182/blood-2002-02-0527. Blood. 2002. PMID: 12149198 Free article. Clinical Trial.
Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cells.
Bornhauser M, Storer B, Slattery JT, Appelbaum FR, Deeg HJ, Hansen J, Martin PJ, McDonald GB, Nichols WG, Radich J, Woolfrey A, Jenke A, Schleyer E, Thiede C, Ehninger G, Anasetti C. Bornhauser M, et al. Among authors: anasetti c. Blood. 2003 Aug 1;102(3):820-6. doi: 10.1182/blood-2002-11-3567. Epub 2003 Apr 3. Blood. 2003. PMID: 12676781 Free article. Clinical Trial.
HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies.
Maris MB, Niederwieser D, Sandmaier BM, Storer B, Stuart M, Maloney D, Petersdorf E, McSweeney P, Pulsipher M, Woolfrey A, Chauncey T, Agura E, Heimfeld S, Slattery J, Hegenbart U, Anasetti C, Blume K, Storb R. Maris MB, et al. Among authors: anasetti c. Blood. 2003 Sep 15;102(6):2021-30. doi: 10.1182/blood-2003-02-0482. Epub 2003 Jun 5. Blood. 2003. PMID: 12791654 Free article. Clinical Trial.
437 results